Geron Corporation
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Harout Semerjian
- Full Time Employees
- 258
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 919 East Hillsdale Boulevard Foster City CA United States of America 94404
- IPO Date
- Jul 31, 1996
- CIK
- 0000886744
- Website
- geron.com
- Similar Companies
- Business
- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company headquartered in Foster City, California and founded in 1990, develops and commercializes telomerase inhibitor therapeutics targeting hematologic malignancies. The company markets RYTELO (imetelstat), a first-in-class telomerase inhibitor indicated for adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia requiring four or more red blood cell units per eight weeks; it explores the broad potential of telomerase inhibition across multiple myeloid hematologic malignancies, including ongoing Phase 3 clinical trials of imetelstat in relapsed/refractory myelofibrosis (IMproveMF trial, NCT04576156) and previously transfusion-dependent anemia in myelodysplastic syndromes (IMerge trial, NCT02598661). Geron operates primarily in the United States with a focus on oncology therapeutics for blood cancers. In November 2024, Geron secured up to $375 million in non-dilutive funding through synthetic royalty financing agreements with Royalty Pharma and Pharmakon Advisors, including an initial $125 million upfront payment for a royalty interest on U.S. net sales of RYTELO to support commercial launch, pipeline advancement, and general corporate purposes. The company reported fourth quarter and full-year 2024 financial results highlighting RYTELO commercialization progress, robust pipeline execution, and increased research and development investments into 2025 for ongoing clinical trials. Geron continues to prioritize global expansion of RYTELO access and telomerase-based therapies without noted acquisitions, partnerships beyond financing, or structural reorganizations in the past two years.
Company News
Did Geron Corporation Insiders Breach their Fiduciary Duties to Shareholders?
Did Geron Corporation Insiders Breach their Fiduciary Duties to Shareholders?
Kuehn Law Encourages Investors of Geron Corporation to Contact Law Firm
Geron to Present at Upcoming Investor Conferences
ADAR1 Capital Management LLC Invests $647,000 in Geron Corporation $GERN
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Geron Corp: Management's Plan Taking Shape As Competition Heats Up In Myelofibrosis
Geron (NASDAQ:GERN) and Shattuck Labs (NASDAQ:STTK) Head to Head Comparison
Geron Corporation (GERN) Q2 2026 Earnings Call Transcript
Geron (GERN) Reports Q2 Loss, Beats Revenue Estimates
Geron Q2 Earnings Call Highlights
Geron Corporation Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Geron (GERN) Expected to Announce Quarterly Earnings on Wednesday
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Geron Plans to Announce Second Quarter 2026 Financial Results on August 5, 2026
Rectify Pharmaceuticals Announces Appointment of Constantine Chinoporos as Executive Chairman
Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Geron Announces Appointment of Chinmaya Rath as Chief Business Officer
Geron Corporation: Commercial Performance Could Dovetail With IMpactMF Run-Up
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)